The relation between serum inflammatory marker levels and serous retinal detachment in macular edema secondary to retinal vein occlusion


Timur İ. E. E., Tarım B., Şeker E. D., UĞURLU N.

Photodiagnosis and Photodynamic Therapy, vol.42, 2023 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 42
  • Publication Date: 2023
  • Doi Number: 10.1016/j.pdpdt.2023.103591
  • Journal Name: Photodiagnosis and Photodynamic Therapy
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
  • Keywords: Macular edema, Optical coherence tomography, Retinal vein occlusion, Serous retinal detachment, Systemic inflammation index
  • Ankara Yıldırım Beyazıt University Affiliated: Yes

Abstract

Purpose: To assess blood-derived inflammatory markers in macular edema (ME) secondary to retinal vein occlusion (RVO) with and without serous retinal detachment (SRD). Materials-Methods: Treatment-naive patients with ME secondary to RVO were divided into two groups according to the existence of SRD in optical coherence tomography (OCT) images; group 1 consisted of 60 patients with SRD, and group 2 consisted of 60 patients without SRD. Age and gender-matched 60 patients formed group 3 as healthy controls. Neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic inflammation index (SII) were calculated from blood samples to assess the differences in the levels of blood-derived inflammatory markers and the presence of SRD. Results: The PLR, NLR, and SII values were higher in groups 1 and 2 than in group 3 (p<0.05, each comparison). The NLR and SII values were also significantly elevated in group 1 compared to group 2 (p = 0.000 and p = 0.000, respectively). The optimal cutoff value to estimate SRD in patients with ME secondary to RVO for NLR was 2.08 with 66.7% sensitivity and 65% specificity; for SII was 530.93 with 68.3% sensitivity and specificity. Conclusion: SII is a reliable and cost-effective tool for predicting SRD, an inflammatory OCT biomarker in ME secondary to RVO.